JP2009523457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523457A5 JP2009523457A5 JP2008551712A JP2008551712A JP2009523457A5 JP 2009523457 A5 JP2009523457 A5 JP 2009523457A5 JP 2008551712 A JP2008551712 A JP 2008551712A JP 2008551712 A JP2008551712 A JP 2008551712A JP 2009523457 A5 JP2009523457 A5 JP 2009523457A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091006116 chimeric peptides Proteins 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108050001049 Extracellular proteins Proteins 0.000 claims 1
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 claims 1
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 108700025763 PTX3 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06001457.8 | 2006-01-24 | ||
| EP06001457 | 2006-01-24 | ||
| PCT/EP2007/000538 WO2007085412A1 (en) | 2006-01-24 | 2007-01-23 | Fgf2-binding peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009523457A JP2009523457A (ja) | 2009-06-25 |
| JP2009523457A5 true JP2009523457A5 (enExample) | 2010-02-25 |
| JP5427415B2 JP5427415B2 (ja) | 2014-02-26 |
Family
ID=37421191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551712A Expired - Fee Related JP5427415B2 (ja) | 2006-01-24 | 2007-01-23 | Ｆｇｆ２結合性ペプチドおよびそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8076300B2 (enExample) |
| EP (1) | EP1973944B1 (enExample) |
| JP (1) | JP5427415B2 (enExample) |
| KR (1) | KR101467453B1 (enExample) |
| CN (1) | CN101384622B (enExample) |
| AU (1) | AU2007209581B2 (enExample) |
| BR (1) | BRPI0707239A8 (enExample) |
| CA (1) | CA2637295C (enExample) |
| DK (1) | DK1973944T3 (enExample) |
| EA (1) | EA015339B1 (enExample) |
| ES (1) | ES2575517T3 (enExample) |
| HR (1) | HRP20160600T1 (enExample) |
| HU (1) | HUE029212T2 (enExample) |
| IL (1) | IL192800A (enExample) |
| MX (1) | MX2008009289A (enExample) |
| PL (1) | PL1973944T3 (enExample) |
| PT (1) | PT1973944T (enExample) |
| SI (1) | SI1973944T1 (enExample) |
| WO (1) | WO2007085412A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204928A1 (en) * | 2017-05-05 | 2018-11-08 | Board Of Regents, The University Of Texas System | Fgl2 monoclonal antibodies and their use in treating malignant tumors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
-
2007
- 2007-01-23 PL PL07702949.4T patent/PL1973944T3/pl unknown
- 2007-01-23 PT PT77029494T patent/PT1973944T/pt unknown
- 2007-01-23 US US12/161,950 patent/US8076300B2/en not_active Expired - Fee Related
- 2007-01-23 HU HUE07702949A patent/HUE029212T2/en unknown
- 2007-01-23 WO PCT/EP2007/000538 patent/WO2007085412A1/en not_active Ceased
- 2007-01-23 JP JP2008551712A patent/JP5427415B2/ja not_active Expired - Fee Related
- 2007-01-23 EP EP07702949.4A patent/EP1973944B1/en active Active
- 2007-01-23 CA CA2637295A patent/CA2637295C/en not_active Expired - Fee Related
- 2007-01-23 DK DK07702949.4T patent/DK1973944T3/en active
- 2007-01-23 SI SI200731788A patent/SI1973944T1/sl unknown
- 2007-01-23 BR BRPI0707239A patent/BRPI0707239A8/pt not_active IP Right Cessation
- 2007-01-23 EA EA200870188A patent/EA015339B1/ru not_active IP Right Cessation
- 2007-01-23 MX MX2008009289A patent/MX2008009289A/es active IP Right Grant
- 2007-01-23 CN CN2007800033499A patent/CN101384622B/zh not_active Expired - Fee Related
- 2007-01-23 AU AU2007209581A patent/AU2007209581B2/en not_active Ceased
- 2007-01-23 HR HRP20160600TT patent/HRP20160600T1/hr unknown
- 2007-01-23 ES ES07702949.4T patent/ES2575517T3/es active Active
-
2008
- 2008-07-14 IL IL192800A patent/IL192800A/en not_active IP Right Cessation
- 2008-08-22 KR KR1020087020664A patent/KR101467453B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7320571B2 (ja) | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 | |
| US8927693B2 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| CN102781960B (zh) | Hsa相关组合物及使用方法 | |
| CN110225924B (zh) | 松弛素融合多肽及其用途 | |
| JP6466376B2 (ja) | 鉄恒常性を制御するための組成物およびそれを用いる方法 | |
| US20160152686A1 (en) | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto | |
| CN101588820A (zh) | α-乳清蛋白组合物 | |
| JP2017529059A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| JP2012529297A5 (enExample) | ||
| JP2008500373A5 (enExample) | ||
| JP2008507298A5 (enExample) | ||
| CN104968796A (zh) | 经修饰纤维黏连蛋白片段或变体及其用途 | |
| JP2013536254A (ja) | インターロイキン−２２のウイルス性肝炎の治療における応用 | |
| WO2008138348A1 (en) | Preparation of complexed lactalbumin | |
| JP2008542685A (ja) | サイトカイン受容体修飾因子及びその使用 | |
| EP3355908A1 (en) | Treatment of bile acid disorders | |
| Pontejo et al. | Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor | |
| CN113747912B (zh) | 重组ccn结构域蛋白和融合蛋白 | |
| US6395875B1 (en) | Recombinant soluble adenovirus receptor | |
| CN101671396A (zh) | 与胶原蛋白特异结合的血管内皮生长因子及其应用 | |
| JP2009523457A5 (enExample) | ||
| JPH05271291A (ja) | 機能性ポリペプチド | |
| Gu et al. | Expression, purification, and bioactivity of human tumstatin from Escherichia coli | |
| WO2011147138A1 (zh) | 靶向性白细胞介素融合蛋白及其制备方法与应用 |